Open Access<p>Double Agent: <em>SPDEF</em> Gene with Both Oncogenic and Tumor-Suppressor Functions in Breast Cancer</p>
Author(s) -
Ting Ye,
Jun Feng,
Xue Wan,
Dan Xie,
Zhibin Wang
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s243748
Subject(s) - suppressor , breast cancer , cancer research , gene , cancer , medicine , biology , genetics
The dichotomy of cancer-regulatory genes into "oncogenes (OCGs)" and "tumor-suppressor genes (TSGs)" has greatly helped us in learning molecular details of tumor biology. SPDEF , known as the prostate-derived ETS factor, is reported to play a pivotal role in normal cell development and survival, which has also been endowed with dual characteristics in cancers. Breast cancer (BC) is a highly heterogeneous disease which becomes the leading reason for cancer-related fatality among women worldwide. The involvement of SPDEF in many aspects of BC has been postulated, whereas the mechanism governing the regulation of the pro- and anti-oncogenic activities of SPDEF in BC state remains poorly defined. In this review, we summarized SPDEF as the double agent involving in expression profiles, the regulatory mechanism in BC progression, as well as the role in diagnosis, treatment and prognosis of BC. The understanding of SPDEF duality has contributed to gain insight into the tumor biology and also add a new dimension to the new therapy targets for BC.